Budget impact analysis of the DiviTum ®TKa assay in postmenopausal women with hormone receptor positive metastatic breast cancer
Conclusions. Clinical use of the DiviTum®TKa assay is expected to decrease traditional imaging and monitoring and may reduce the overall cost of managing mBC if it leads to clinical decisions to avoid futile therapy. Post-coverage, real world monitoring of palliative therapies among post-menopausal mBC populations is needed to better categorize cost savings over time.PMID:34763605 | DOI:10.1080/13696998.2021.2003674
Source: Journal of Medical Economics - Category: Health Management Authors: Josh J Carlson Gregory F Guzauskas Robert A Dann Scott D Ramsey Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | CT Scan | Economics | Health Management | HER2 | Hormones | Men | Menopause | Palliative | PET Scan | Women